Table: Takeda Pharma -9-MTH group results (IFRS)

Takeda Pharmaceutical

29/01/2026 06:31

Jan 29 (Reuters)- 
              Takeda Pharmaceutical Co. Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2025        Dec 31, 2024     Mar 31, 2026 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales             3.41 trln           3.53 trln        4.53 trln  
                   (-3.3 pct)          (+9.8 pct)       (-1.1 pct)  
  Operating          422.38              417.52           410.00    
                   (+1.2 pct)          (+86.3 pct)      (+19.7 pct) 
  Pretax             312.67              282.38           245.00    
                   (+10.7 pct)        (+181.5 pct)      (+39.9 pct) 
  Net                216.08              211.08           154.00    
                   (+2.4 pct)          (+43.5 pct)      (+42.7 pct) 
  EPS Basic        137.31 yen          133.71 yen        97.78 yen  
  EPS Diluted      135.13 yen          131.69 yen                   
  Ann Div                              196.00 yen       200.00 yen  
  -Q2 Div          100.00 yen           98.00 yen                   
  -Q4 Div                               98.00 yen       100.00 yen  
 
  NOTE - Takeda Pharmaceutical Co. Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4502.T